HOME >> MEDICINE >> NEWS
Novel drugs help solve Gleevec resistance

SAN DIEGO - Two different novel targeted therapies can produce strong responses in patients who have become resistant to Gleevec(tm), the standard therapy for chronic myeloid leukemia (CML), researchers at The University of Texas M. D. Anderson Cancer Center are reporting.

Researchers say the benefits offered by these drugs, BMS-354825 and AMN107, appear to be promising for treatment of relapsed CML and offer an immediate effective option for the minority of patients who do not achieve an optimal response to Gleevec therapy.

M. D. Anderson Cancer Center, the only institution to have tested both of these novel compounds, undertook independent Phase I clinical trials of both agents. It conducted the study of BMS-354825 in conjunction with the University of California, Los Angeles, and the study of AMN107 with the University of Frankfurt, in Germany. The M. D. Anderson researchers will discuss their experiences using these agents in patients with leukemia at the American Society of Hematology (ASH) meeting.

BMS-354825 "shows remarkable activity"

In the study conducted at M. D. Anderson and at UCLA School of Medicine, the majority of patients with advanced, Gleevec-resistant CML have responded to the drug BMS-354825, says Moshe Talpaz, M.D., a professor in the Department of Experimental Therapeutics at M. D. Anderson.

Of 11 patients with advanced "blast phase" CML, seven have had a hematologic response from the drug (defined as control of white blood cell counts). Of these, three patients experienced a complete hematologic response (disappearance of all findings consistent with advanced stage CML, and return of blood counts to normal), while two patients showed no evidence of leukemia. Two other patients had their CML downgraded to "chronic." Additionally, of the 11 patients, four have had a major "cytogenetic response" (defined as elimination of cells with the cancer-causing defect), and two had minor cytogenetic response
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
5-Dec-2004


Page: 1 2 3 4 5

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel imaging technique shows abnormal brain anatomy in children with ADHD
5. Novel drug-antidote strategy provides greater control of drug action
6. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
7. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
8. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
9. Novel findings about neovessel formation
10. Novel MRI technique provides clear images of blood flow
11. Novelty-seeking teens may be more easily influenced by tobacco advertisements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/5/2020)... ... 2020 , ... COVID-19 presented a global challenge to all ... rapid spread of illness is no small task and is further complicated by ... single solution—a framework is required. To that end, DeCurtis Corporation, the leader in ...
(Date:6/4/2020)... ... June 04, 2020 , ... When it comes to starting the ... to end. Optimistically confronting our most challenging task first. When we’re done with our ... you experience high demands at work with little or no control of each task? ...
(Date:6/4/2020)... ... 04, 2020 , ... The experience of making or watching a film in ... Then came the COVID-19 pandemic and physical distancing. “The German film industry came to ... Festival (BIFF). That is, “all stages of the film business, exhibition, production, financing - ...
(Date:6/2/2020)... ... June 02, 2020 , ... RemetricHealth , a ... the healthcare industry for more than a decade, announced today the launch of ... , In 2010, RemetricHealth, then known as PMD Healthcare, developed the first-ever patented, ...
(Date:5/30/2020)... ... May 29, 2020 , ... Segal Trials, a ... Phase I-IV trials, commemorated May, Mental Health Awareness Month, and May 20th, Clinical ... , Efforts include their #StayConnected video series raising awareness of clinical trials ...
Breaking Medicine News(10 mins):
(Date:5/30/2020)... ... May 30, 2020 , ... Pregnancy is stressful already, ... issues related to COVID-19. Recently, Wellness Expert Jamie Hess teamed with One A ... pregnancy and postpartum. , A video accompanying this announcement is available at: ...
(Date:5/28/2020)... Ill. (PRWEB) , ... May 28, 2020 , ... ... telehealth and remote patient-care products led M&S Technologies, leader and innovator in essential ... introduction of M&S Technologies ’ web-based Vision Testing has been released and ...
(Date:5/27/2020)... ... May 27, 2020 , ... ... Taub , a biomedical engineer with more than 25 years of experience in ... the firm as an Expert Consultant. His expertise includes quality assurance, including ISO ...
Breaking Medicine Technology:
Cached News: